» Articles » PMID: 3978036

Accumulation of Inflammatory Cells in Response to Intracutaneous Platelet Activating Factor (Paf-acether) in Man

Overview
Journal Br J Dermatol
Date 1985 Mar 1
PMID 3978036
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet activating factor (Paf-acether, AGEPC) is a family of ether-linked phospholipids known to be released from a range of inflammatory cell types. In vitro and in experimental animals, it seems to be a mediator of inflammation, and intradermal injection of Paf-acether in man elicits a biphasic inflammatory response, reminiscent of the dual response to allergen in sensitized individuals. In the present study, cutaneous histology was assessed in sequential skin biopsies from six normal volunteers after intradermal injection of 200 or 800 pmol Paf-acether. Paf-acether (200 pmol) induced intravascular accumulation of neutrophils, accompanied by a perivascular mixed cellular infiltrate which was composed predominantly of neutrophils at 4 and 12 hours, and lymphocytes and histiocytes at 24 hours. Control injections of lyso-Paf and normal saline induced no noteworthy histological changes. Paf-acether (800 pmol) resulted in vessel destruction, gross endothelial swelling and a perivascular infiltrate of mononuclear cells and neutrophils, accompanied by occasional evidence of leucocytoclasis. By virtue of its ability to induce inflammatory cell accumulation in human skin, Paf-acether should be considered as a potential mediator of inflammatory disorders such as psoriasis.

Citing Articles

Lysophospholipids in the Mediterranean sponge Oscarella tuberculata: seasonal variability and putative biological role.

Ivanisevic J, Perez T, Ereskovsky A, Barnathan G, Thomas O J Chem Ecol. 2011; 37(5):537-45.

PMID: 21479567 DOI: 10.1007/s10886-011-9943-2.


Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Singh T, Huettner B, Koefeler H, Mayer G, Bambach I, Wallbrecht K Am J Pathol. 2011; 178(2):699-708.

PMID: 21281802 PMC: 3070583. DOI: 10.1016/j.ajpath.2010.10.008.


Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice.

Kemeny L, Trach V, Dobozy A Arch Dermatol Res. 1996; 288(8):492-4.

PMID: 8844132 DOI: 10.1007/BF02505242.


Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

Barr R, Lawlor F, Judge M, Courtney P, Barlow R, Kobza Black A Br J Clin Pharmacol. 1993; 35(6):637-41.

PMID: 8329291 PMC: 1381608. DOI: 10.1111/j.1365-2125.1993.tb04194.x.


Platelet activating factor (PAF) and lyso-PAF in psoriasis.

Judge M, Barr R, Mallet A, Courtney F, Kobza Black A, Greaves M Arch Dermatol Res. 1994; 286(7):376-9.

PMID: 7818279 DOI: 10.1007/BF00371796.